Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 20...
30 Juillet 2014 - 10:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it
will host a webcast and conference call to discuss the Company's
financial results for the quarter ended June 30, 2014 and provide a
general business overview on Wednesday, August 6, 2014 at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (877) 299-4454
from the U.S. and Canada, or +1(617) 597-5447 internationally, and
use the passcode 61060299. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that have the potential to represent
significant advances in the fields of thrombosis and other
hematologic diseases. The Company is advancing its three
wholly-owned programs using novel biomarker and genetic approaches
that may increase the likelihood of clinical, regulatory and
commercial success of its potentially life-saving therapies.
Portola's partnered program is focused on developing selective Syk
inhibitors for inflammatory conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in the only biomarker-based Phase 3
study for hospital-to-home prophylaxis of venous thromboembolism
(VTE) in acute medically ill patients. Betrixaban's distinct
properties may have the potential to allow the agent to demonstrate
efficacy without the significant increase in the rate of major
bleeding that was seen in this patient population with other Factor
Xa inhibitors. If approved, betrixaban could be the first
anticoagulant for both hospital and post-discharge VTE prophylaxis
and the standard of care in this large market of more than 20
million patients worldwide.
Andexanet Alfa
Andexanet alfa, a recombinant modified Factor Xa molecule, has
the potential to be a first-in-class antidote to reverse the
effects of Factor Xa inhibitors in patients who suffer a major
bleeding episode or who require emergency surgery. Andexanet alfa
has been designated as a breakthrough therapy by the U.S. Food and
Drug Administration. Portola has entered into clinical
collaboration agreements with all of the manufacturers of direct
Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer
(Eliquis® [apixaban]), Bayer HealthCare and Janssen
Pharmaceuticals (XARELTO® [rivaroxaban]), and Daiichi Sankyo
(edoxaban) – while retaining all commercial rights to andexanet
alfa. The Company is currently evaluating andexanet alfa in the
Phase 3 ANNEXA™ (Andexanet Alfa a Novel Antidote to the
Anticoagulant Effects of fXA Inhibitors) registration studies.
Cerdulatinib* (PRT2070)
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways – spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
evaluated in a Phase 1/2 proof-of-concept study in patients with
leukemias or lymphomas with a focus on genetically-defined
subtypes, as well as in patients who have failed therapy due to
relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
*Cerdulatinib is a proposed International Nonproprietary Name
(pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024